US Patent Issued to Vakston on July 1 for "Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use" (Massachusetts, California Inventors)

ALEXANDRIA, Va., July 3 -- United States Patent no. 12,343,393, issued on July 1, was assigned to Vakston Inc. (Beverly, Mass.).

"Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use" was invented by Todd C. Zion (Marblehead, Mass.), Thomas M. Lancaster (Wenham, Mass.), Thillainayagam Sathiyaseelan (Lexington, Mass.) and Kexin Huang (San Mateo, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the admi...